Europe gives generics merger the green flag


 

Two of the top five global generic medicines manufactures, Watson and Actavis, have been given the go-ahead to merge by the European Commission. Under the deal, Watson – which is predominantly active in the US – will acquire Actavis for €4.25 billion (£3.4 billion).

The combined company will become the third largest generics business in the world, after Israel’s Teva, and Sandoz, the generics arm of Swiss firm Novartis. According to Watson’s chief executive, Paul Bisaro, the aim of the acquisition is to strengthen the company’s position outside of the US. ‘In a single, commercially compelling transaction, we more than double Watson's international access and strengthen our commercial position in key established European markets as well as exciting emerging growth markets, including Central and Eastern Europe and Russia,’ he says.


Related Content

Megamerger brings Actavis into R&D race

25 February 2014 Business

news image

$25bn Forest Labs takeover will see generics giant take on patented products

Business roundup

28 July 2011 Business

news image

Industry news, August 2011

Most Read

Self-cleaning sensors see the light

23 January 2015 Research

news image

Overcoming electrode fouling in biomedical and environmental detectors

Alkali metal explosion explained

26 January 2015 Research

news image

High-speed cameras help re-examine the chemistry behind a classic classroom demonstration

Most Commented

Undeniable: evolution and the science of creation

7 January 2015 Review

news image

Evolutionary arguments

Alkali metal explosion explained

26 January 2015 Research

news image

High-speed cameras help re-examine the chemistry behind a classic classroom demonstration